Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML6QJN)

• Drug Name: SDZ-MKS-492 Drug Info
• Synonyms: MKS-492

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 163931
  CAS Number: CAS 114606-56-3
  TTD Drug ID: DML6QJN

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 3 (PDE3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[2]
Oxtriphylline	DMLHSE3	Cough	MD12	Approved	[2]
Ibudilast	DM4LSPN	Castleman's disease	4B2Y	Approved	[3]
Enoximone	DMQVZJD	Congestive heart failure	BD10	Approved	[4]
Olprinone	DMWBQKU	Heart failure	BD10-BD13	Approved	[5]
Inamrinone Lactate	DMRMFP4	Cardiac disease	BA00-BE2Z	Approved	[6]
Milrinone	DM8TUPF	Congestive heart failure	BD10	Approved	[2]
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[7]
Tipelukast	DMS9BDQ	Asthma	CA23	Phase 2	[8]
RPL-554	DMLD4VQ	Allergic rhinitis	CA08.0	Phase 2	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 3 (PDE3)	TTZCG4L	NOUNIPROTAC	Modulator	[1]

References

• [1] Effects of a cyclic nucleotide phosphodiesterase isoenzyme type III inhibitor, SDZ MKS 492 on airway responsiveness in beagles. Arerugi. 1993 Aug;42(8):920-5.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
• [4] In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
• [5] Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
• [6] Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
• [7] The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
• [8] Company report (MediciNova)
• [9] Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.